HPV 52 would not have been identified if present in co-infection with HPV 33, 35 or 58. As genotyping Talazoparib molecular weight was only
conducted on those samples found to be positive by hc2, HPV types 26, 40, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73 (MM9), 81, 82 (MM4), 83 (MM7), 84 (MM8), IS39, and CP6108 would only have been identified in co-infection with one or more of the types included on the hc2 probes or through cross-reactivity to probes not directly targeting the type [12]. The volume of VVS samples submitted to the study varied and a workable sample volume was determined to be 300 μL of starting material for both hc2 and LA. VVS samples were estimated to contain only 7% of the cellular material found in liquid based cytology (LBC) samples (median 345,362 [IQR: 166,540–538,063] (n = 29) and 4,932,320
[IQR: 2,211,951–8,687,917] (n = 51) cell equivalents respectively), using a TaqMan®-based real-time PCR for glyceraldehyde-3-phosphate dehydrogenase [13]. A small panel of LBC samples (n = 64; 43 positive by LA, 21 negative) were evaluated in hc2 at (i) the recommended input find more volume for LBC samples; and (ii) with the input volume normalized to the cell equivalents found in 300 μL of VVS samples. At the recommended input volume the sensitivity of hc2 compared to LA was 88% and at the level of cell equivalents used in this study it was 77%. Both of these cellular concentrations had a specificity of 100%. The results for LBC samples at
the recommended input were consistent with the literature [14], [15] and [16]. For LA, the VVS sample input was estimated to contain approximately 70% of the cell equivalents of the manufacturer recommended volume of LBC sample (ca. 17,270 compared to ca. 24,660 cell equivalents respectively [4]). This difference was not expected to have an impact on the performance of LA. HR HPV types (-)-p-Bromotetramisole Oxalate were defined according to the 2009 International Agency Research on Cancer classification of types which were at least ‘probably carcinogenic to humans’ in the cervix: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 [17]. These types are all included on the hc2 high risk probe and identified by LA. One DNA extraction run of 88 hc2 positive samples (being processed for subsequent genotyping) failed. We excluded from the analysis all samples included on the four hc2 plates from which these 88 samples originated (thereby excluding a further 187 eligible samples). An additional 15 hc2 positive samples had invalid LA results.